Spyre Therapeutics
SYRE
83 hedge funds and large institutions have $95.4M invested in Spyre Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 12 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.12% more ownership
Funds ownership: 3.24% → 3.36% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 85 → 83 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
50% less capital invested
Capital invested by funds: $189M → $95.4M (-$93.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$5M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.31M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.65M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.3M |
| 5 |
SCM
Sio Capital Management
New York
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.96M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.75M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.32M |
| 4 |
Axa
Paris,
France
|
-$2.11M |
| 5 |
ACM
Altium Capital Management
New York
|
-$1.4M |
SYRE Hedge Fund Activity: Q1 2022 in Review
83 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2022, worth a combined $95.4M — down 50% from $189M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SYRE and 10 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was Suvretta Capital Management, adding an estimated $5M. The largest seller was Artal Group, exiting entirely with an estimated $4.96M sold.
- 83 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2022, down from 85 in Q4 2021.
- Funds reported $95.4M of Spyre Therapeutics stock for Q1 2022, down 50% quarter-over-quarter.
- 10 funds opened new Spyre Therapeutics positions in Q1 2022 and 12 closed out, a net change of -2 holders.
- The largest Spyre Therapeutics buyer in Q1 2022 was Suvretta Capital Management, an estimated $5M added.
- The largest Spyre Therapeutics seller in Q1 2022 was Artal Group, an estimated $4.96M sold.
Based on aggregated 13F filings for Q1 2022.